P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC .
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Metastatic Triple Negative Breast Cancer
Interventions: DRUG: Sabizabulin|DRUG: Sacituzumab Govitecan-hziy|DRUG: Sabizabulin/Sacituzumab govitecan-hziy Combo
Sponsor: Veru Inc.